Forgetting where the car keys are is normal. Forgetting how to get home from a neighborhood driven a thousand times is not. That distinction, between ordinary age-related forgetfulness and changes that interfere with daily independence, sits at the heart of understanding Alzheimer’s disease.
Alzheimer’s is the most common cause of dementia, but the two terms are not interchangeable. Dementia describes a broad decline in cognitive function severe enough to interfere with daily life, and Alzheimer’s is one specific disease that causes it, alongside vascular dementia, Lewy body dementia, and several other conditions.
Diagnosis and treatment for Alzheimer’s have changed substantially in recent years, as blood-based biomarkers and disease-modifying therapies move from research settings into everyday clinical practice. This guide walks through symptoms, causes, diagnosis, current treatment options, and the companies shaping where care is headed next.
What Is Alzheimer’s Disease?
Alzheimer’s disease is a progressive brain disorder that gradually impairs memory, thinking, and the ability to carry out everyday tasks. It affects more than 6.5 million Americans, according to the FDA, and its prevalence rises sharply with age.
The disease is associated with two hallmark changes in the brain: the buildup of amyloid beta plaques between neurons and the formation of tau protein tangles inside neurons. These changes are believed to contribute to the loss of neurons and neural connections that drives the disease, though researchers continue to study how these processes interact with other biological factors.
The First Signs Are Often More Than Forgetfulness
Early Alzheimer’s symptoms extend well beyond simple forgetfulness, though memory problems are frequently the most noticeable early sign. The National Institute on Aging identifies several patterns worth paying attention to.
Repeating the same questions within a short period is a common early symptom, as is difficulty managing finances or keeping track of bills. Losing track of dates, seasons, or familiar locations can also emerge early. Trouble finding the right words during conversation, difficulty completing familiar tasks like following a recipe, and noticeable changes in judgment or personality round out the pattern clinicians look for.
No single symptom confirms Alzheimer’s on its own. It is the combination and progression of these changes, particularly when they interfere with independence, that prompts further evaluation.
Alzheimer’s Progresses Differently From Person to Person
Clinicians generally describe Alzheimer’s progression in mild, moderate, and severe stages, though the pace and specific symptoms vary considerably between individuals. Mild stage changes typically involve memory lapses and mild difficulty with complex tasks while independence remains largely intact.
Moderate stage Alzheimer’s often brings more noticeable confusion, difficulty recognizing people, and a growing need for assistance with daily activities. Severe stage Alzheimer’s typically involves significant loss of communication ability and near total dependence on caregivers. These stages are useful for understanding general progression, not as a fixed timetable that applies uniformly to every patient.
What Causes Alzheimer’s Disease?
Alzheimer’s develops through a complex interaction of age, genetics, and brain changes that researchers are still working to fully understand. Age remains the strongest known risk factor, with risk rising substantially after age 65.
Genetic factors play a meaningful role for some individuals. The APOE gene, particularly the APOE e4 variant, is associated with increased risk of developing Alzheimer’s and increased risk of certain treatment complications, though carrying this gene variant does not guarantee a person will develop the disease. It is important to distinguish risk from certainty here, since genetics represents one contributing factor among many rather than a deterministic cause.
Alzheimer’s vs Other Causes of Memory Problems
Not every case of memory decline is Alzheimer’s disease, which is exactly why proper diagnosis matters. Several other conditions can produce similar symptoms.
Normal aging can bring mild forgetfulness that does not interfere with independence. Depression can mimic cognitive decline in what clinicians sometimes call pseudodementia. Certain medications can cause confusion or memory problems as a side effect. Thyroid disorders and vitamin deficiencies, particularly vitamin B12 deficiency, can both produce cognitive symptoms that improve once the underlying issue is treated. Vascular cognitive impairment, caused by reduced blood flow to the brain, presents differently from Alzheimer’s and often has a different treatment approach. Distinguishing between these possibilities matters because some causes of cognitive symptoms are treatable or reversible, while Alzheimer’s currently is not.
How Alzheimer’s Is Diagnosed Today
Diagnosis typically begins with a detailed clinical history, cognitive assessment, and neurological examination. Laboratory tests help rule out reversible causes like thyroid dysfunction or vitamin deficiencies, and brain imaging can identify structural changes or rule out other conditions.
Biomarker testing has become an increasingly important part of the diagnostic picture. Blood-based biomarkers, cerebrospinal fluid analysis, and amyloid PET imaging can all help confirm the presence of Alzheimer’s related brain changes. According to the National Institute on Aging, biomarkers are increasingly helping with dementia detection and research, though availability and standardized clinical use continue to evolve across different healthcare settings. Amyloid PET imaging remains a diagnostic gold standard in many clinical contexts, while blood-based tests are gaining traction as a less invasive first step.
What Happens After a Diagnosis?
A diagnosis marks the beginning of a planning process rather than an endpoint. Confirming the diagnosis and understanding which stage the disease has reached comes first, followed by a review of available treatment options with a specialist.
Reviewing current medications for potential interactions or contributing factors is an important next step. Addressing home safety, including driving ability and fall risk, protects both the patient and those around them. Advance care planning, ideally started while the patient can still participate meaningfully in decisions, helps ensure future care aligns with their wishes. Connecting with caregiver support resources and addressing financial and legal planning round out the practical next steps that families typically need to work through.
Current Alzheimer’s Treatments
Medicines for Cognitive Symptoms
Cholinesterase inhibitors work by increasing levels of a neurotransmitter involved in memory and thinking, and they are commonly prescribed for mild to moderate Alzheimer’s to help manage cognitive symptoms.
Memantine
Memantine works through a different mechanism, regulating glutamate activity in the brain, and is typically used for moderate to severe Alzheimer’s, sometimes in combination with a cholinesterase inhibitor.
Medicines for Selected Behavioral Symptoms
Some patients experience behavioral symptoms like agitation or sleep disturbance as the disease progresses. Treatment for these symptoms requires careful risk-benefit consideration, since certain medications carry meaningful safety concerns in people with dementia, and non-pharmacologic approaches are often tried first.
Disease Modifying Alzheimer’s Therapies
Two anti-amyloid therapies, lecanemab (Leqembi) and donanemab (Kisunla), represent a genuine shift in Alzheimer’s treatment. Both received traditional FDA approval, lecanemab in July 2023 and donanemab in July 2024, and both are indicated for people with early Alzheimer’s disease, specifically mild cognitive impairment or mild dementia with confirmed elevated brain amyloid.
Lecanemab is administered as an intravenous infusion, initially every two weeks, with an FDA-approved maintenance option that allows less frequent dosing after 18 months of treatment. Donanemab is administered by infusion every four weeks and offers the possibility of stopping treatment once brain scans confirm amyloid has been cleared.
Neither drug is a cure. Clinical trial data showed both therapies slow the rate of cognitive and functional decline in appropriately selected early-stage patients, allowing more time for independent daily living, but they do not reverse damage that has already occurred.
What Are the Major Safety Questions With New Alzheimer’s Drugs?
Both lecanemab and donanemab carry a risk of a side effect known as amyloid-related imaging abnormalities, or ARIA, which involves brain swelling or small areas of bleeding detected through MRI scans. Most cases resolve without lasting symptoms, but rare cases have been serious, including seizures in cases of significant swelling and, rarely, fatal bleeding.
People carrying the APOE e4 gene variant face a higher risk of ARIA, which is why the FDA recommends genetic testing before starting treatment. A baseline brain MRI is required before starting treatment, with periodic follow-up MRI scans during the treatment course to monitor for these complications. Anyone taking blood-thinning medication should discuss that risk carefully with their prescribing physician before starting either therapy.
Companies Shaping the Alzheimer’s Treatment Landscape
The current treatment landscape spans several distinct roles across the pharmaceutical and diagnostics industry.
Approved disease-modifying therapies are led by Eisai and Biogen, which jointly developed and market lecanemab (Leqembi), and Eli Lilly, which developed donanemab (Kisunla). Both companies continue to refine dosing options, including newer subcutaneous formulations designed to reduce treatment burden for patients and caregivers.
Symptom treatment medications, including cholinesterase inhibitors and memantine, are produced by multiple established pharmaceutical manufacturers, many available in generic form after original patents expired.
Diagnostic biomarker development involves companies building blood-based tests intended to detect Alzheimer’s related brain changes with less invasive methods than traditional cerebrospinal fluid testing or PET imaging.
Imaging technology companies continue to refine amyloid and tau PET imaging agents that support both diagnosis and treatment monitoring.
Emerging drug candidates currently in development target additional mechanisms beyond amyloid clearance, including tau pathology and neuroprotective approaches, with several companies running active clinical trials exploring these newer strategies.
Regulatory status and trial results in this space change quickly, so anyone researching a specific company or drug candidate should verify current status directly through the FDA, ClinicalTrials.gov, or the company’s own investor and clinical communications before drawing conclusions about approval timelines.
What Could Change Alzheimer’s Care Next?
Several developments are likely to shape Alzheimer’s care in the coming years. Blood-based biomarkers could make earlier, less invasive diagnosis more widely accessible outside of specialized memory clinics. Combination treatments targeting multiple disease mechanisms simultaneously are under active investigation. New therapeutic targets beyond amyloid, including tau protein and neuroinflammation pathways, continue to generate research interest.
It is worth being clear about the distinction between established clinical practice and emerging research. Approved therapies like lecanemab and donanemab represent the current standard of care for eligible early-stage patients, while many of the newer approaches described above remain in clinical trials and have not yet reached regulatory approval.
Alzheimer’s care is shifting from a model centered almost entirely on symptom management toward one that includes earlier biological diagnosis and disease-modifying treatment for appropriately selected patients. That shift does not change the most important practical takeaway for families noticing concerning cognitive changes: earlier evaluation creates more treatment options, not fewer, and waiting until symptoms become severe closes doors that might otherwise stay open.
FAQ
Q: What are the first signs of Alzheimer’s disease?
A: Common early signs include repeating questions, difficulty managing finances, losing track of dates or locations, and trouble finding words. Changes in judgment or personality can also appear early in the disease course.
Q: What is the difference between Alzheimer’s and dementia?
A: Dementia is a general term for cognitive decline severe enough to interfere with daily life, while Alzheimer’s is one specific disease that causes dementia. Alzheimer’s is the most common cause of dementia, but not the only one.
Q: What causes Alzheimer’s disease?
A: Alzheimer’s results from a combination of age, genetic factors, and brain changes involving amyloid plaques and tau tangles. Researchers continue to study exactly how these factors interact to cause the disease.
Q: How is Alzheimer’s diagnosed?
A: Diagnosis involves clinical history, cognitive testing, neurological examination, lab tests to rule out other causes, and often brain imaging or biomarker testing. Amyloid PET imaging and blood-based biomarkers can help confirm Alzheimer’s related brain changes.
Q: Can a blood test detect Alzheimer’s disease?
A: Blood-based biomarker tests are increasingly used to help detect Alzheimer’s related brain changes, though availability and clinical use continue to expand. They are often used alongside other diagnostic tools rather than as a standalone diagnosis.
Q: Is there a cure for Alzheimer’s?
A: There is currently no cure for Alzheimer’s disease. Approved therapies like lecanemab and donanemab can slow disease progression in early-stage patients but do not reverse existing damage.
Q: What medications are used for Alzheimer’s?
A: Cholinesterase inhibitors and memantine are commonly used to manage cognitive symptoms, while lecanemab and donanemab are approved disease-modifying therapies for early-stage disease. Treatment selection depends on disease stage and individual patient factors.
Q: What are lecanemab and donanemab?
A: Lecanemab (Leqembi) and donanemab (Kisunla) are FDA-approved anti-amyloid antibody therapies for early Alzheimer’s disease. Both work by clearing amyloid plaques from the brain and have been shown to slow cognitive decline in appropriately selected patients.
Q: Can Alzheimer’s disease be prevented?
A: There is no guaranteed way to prevent Alzheimer’s disease, though some research suggests cardiovascular health, physical activity, and cognitive engagement may support overall brain health. Genetics and age remain risk factors that cannot be controlled.
Q: How quickly does Alzheimer’s progress?
A: Progression varies significantly between individuals and cannot be reliably predicted at diagnosis. Some people remain in early stages for several years, while others progress more quickly.
Q: Which companies are developing Alzheimer’s treatments?
A: Eisai and Biogen jointly market lecanemab, while Eli Lilly developed donanemab, both currently approved for early Alzheimer’s disease. Numerous other companies are developing diagnostic biomarkers and next-generation drug candidates targeting different disease mechanisms.
Medical Disclaimer: This article is for general educational purposes only and is not a substitute for professional medical advice. Memory problems and cognitive changes should be evaluated by a qualified healthcare provider, since online information cannot establish a diagnosis. Drug approval status and clinical trial information change frequently and should be verified through the FDA and ClinicalTrials.gov before making treatment decisions.